Zakrzewski, Johannes L
van den Brink, Marcel R M
Hubbell, Jeffrey A
Article History
Received: 24 February 2014
Accepted: 14 June 2014
First Online: 5 August 2014
Competing interests
: Jeffrey Hubbell wishes to declare that he is founder and shareholder of Anokion SA, which is commercializing the technology described in the manuscript regarding binding antigens to erythrocytes for tolerization.